Valeant Pharmaceuticals said it expects to file its first-quarter report with U.S. and Canadian regulators on or before June 10, ahead of a July 31 deadline and reiterated its first-quarter forecasts.
The Canadian drugmaker's U.S.-listed shares were up 4.6 percent at $31.27 in premarket trading on Monday.
Valeant also said it expects the filings for the second quarter ending June 30 and thereafter to be filed on a timely basis with the Securities and Exchange Commission and the Canadian Securities regulators.
Embattled Valeant filed its 2015 financial report last month meeting an important deadline for creditors. The filing allayed concerns about a possible default on the company's debt of more than $30 billion.
The company, which also reiterated its first-quarter revenue and adjusted earnings forecast, has been facing scrutiny from the U.S. Congress, prosecutors, and regulators over its drug pricing, business practices and accounting practices.